DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Rekvina Labs Ltd (VINRKLB) share price today?

Rekvina Labs Ltd (VINRKLB) is trading at ₹28 on the BSE, down 4.86% on the day. Source: DocStoX.

What is the market capitalisation of Rekvina Labs Ltd?

Rekvina Labs Ltd has a market capitalisation of approximately ₹18 crore.

Rekvina Labs Ltd

VINRKLB·BSE·Healthcare

₹28.00▼ -1.43 (-4.86%)

Healthcare · Pharmaceuticals & Biotechnology

Debt-free and consistently profitable

Day₹27.97

₹28.05

52W₹7

₹4753%

Open

₹27.97

High

₹28.05

Low

₹27.97

Prev Close

₹29.43

Volume

120

VWAP

₹27.98

Snapshot

Key fundamentals

Market Cap

₹18 Cr

P/E Ratio

N/A

P/B Ratio

-14.47

EPS

₹-0.12

Book Value

N/A

ROE

41.27%Strong

ROCE

41.27%Efficient

Dividend Yield

0.00%

Debt / Equity

0.00Low

Face Value

₹5.00

52W High

₹46.65

52W Low

₹6.75

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Fairly Valued

Narrow moatHigh uncertainty

Fair value unavailable

/100

Business quality — Solid

Growth 50Profitability 50Efficiency 100Valuation 100

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet

Strengths

Virtually debt-free balance sheet
Strong returns on equity (41%)
Capital is working hard (ROCE 41%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

—

ROE

41.3%Strong

Above 15% is considered healthy for Indian equities

ROCE

41.3%Efficient

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹18 Cr

P/B

-14.47

EPS

₹-0.12

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

N/A

No P/E

Growth

N/A

No history

Profitability

Excellent

41.3% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹3,357 Cr

Trades3

VWAP₹27.98

Face value₹5.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

—

10Y

+45.4%

Profit

—

10Y

—

EPS

—

10Y

—

Profile

Cons

Company has low interest coverage ratio.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

41%

Promoter

Promoters

41.3%0.00

Public

45.9%-0.11

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

12.8%

Total shareholders

2,475+1,972 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter41.30%

Public45.88%

Others12.82%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

[1]Rekvina Laboratories Limited is engaged in the manufacturing and marketing of pharmaceutical formulations.[2]

Rekvina Labs Ltd valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

Rekvina Labs Ltd peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Ltd Divis Laboratories Ltd Torrent Pharmaceuticals Ltd Apollo Hospitals Enterprise Ltd Zydus Lifesciences Ltd Cipla Ltd Lupin Ltd Max Healthcare Institute Ltd Mankind Pharma Ltd Dr Reddys Laboratories Ltd Aurobindo Pharma Ltd Laurus Labs Ltd

Compare Rekvina Labs Ltd with peers

Rekvina Labs Ltd vs Sun Pharmaceutical Industries Ltd Rekvina Labs Ltd vs Divis Laboratories Ltd Rekvina Labs Ltd vs Torrent Pharmaceuticals Ltd Rekvina Labs Ltd vs Apollo Hospitals Enterprise Ltd Rekvina Labs Ltd vs Zydus Lifesciences Ltd Rekvina Labs Ltd vs Cipla Ltd

Related tools & concepts

Value Rekvina Labs Ltd with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Rekvina Labs Ltd

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

Rekvina Labs Ltd valuation & research

Rekvina Labs Ltd peers in Healthcare

Compare Rekvina Labs Ltd with peers

Related tools & concepts

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Cons

Ownership breakdown

Ownership over time

Frequently asked questions